Outlook Therapeutics Inc. — LYTENAVA (bevacizumab-vikg) / ONS-5010 - (NO · Wet age-related macular degeneration (wet AMD).
Run-up into the decision (T-120 → T+5)
Daily close, T-120 (10/21/25) through T+5. Run-up high $2.47 on 12/23/25, low $0.198 on 3/25/26 (T-120 to T-1). FDA decision 4/7/26. Historical price action, not a forecast.
Key facts
FDA decision date2026-04-07
OutcomeCRL
Drug / candidateLYTENAVA (bevacizumab-vikg) / ONS-5010 - (NO